Insights

PTAB Rejects Flawed Inherency Argument Against Drug Composition Patent, <i>PTAB Litigation Blog</i>

PTAB Rejects Flawed Inherency Argument Against Drug Composition Patent, PTAB Litigation Blog

Visit the Jones Day PTAB Litigation Blog.

On February 3, 2017, the PTAB denied a petition by Amneal Pharmaceuticals LLC ("Amneal") to institute an inter partes review of Hospira Inc.’s patent directed to pharmaceutical compositions of the sedative dexmedetomidine.

Read the full article at ptablitigationblog.com.

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.